This website sells research peptides exclusively for scientific and laboratory research purposes.
Do you confirm you are 18+ and accessing this site for legitimate research purposes?
CJC-1295 with DAC (Drug Affinity Complex) has a significantly extended half-life of approximately 8 days compared to CJC-1295 No DAC (Modified GRF 1-29) which has a half-life of approximately 30 minutes. This pharmacokinetic difference fundamentally changes the research application of each variant. CJC-1295 with DAC research examines sustained, continuous GH elevation patterns and their downstream effects on IGF-1 levels over extended periods. CJC-1295 No DAC research studies more physiological GH pulse responses, mimicking the natural pulsatile secretion pattern of endogenous GHRH. The DAC modification works by binding albumin in the bloodstream, dramatically extending the half-life. Research examining both variants has explored the importance of GH pulse pattern versus sustained elevation in various biological outcomes. The No DAC variant is typically studied in combination with GHRP compounds to examine synergistic pulsatile GH release, while the DAC variant is studied for sustained GH axis stimulation protocols.
